ArticleJACC. Asia2026
Multimorbidity Status Worsening and Clinical Outcomes of Patients With Atrial Fibrillation.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComorbidities are associated with adverse outcomes in patients with atrial fibrillation (AF).
objectivesThe authors aimed to assess the impact of changes in multimorbidity status on clinical outcomes and the impact of Atrial Fibrillation Better Care (ABC) adherence of patients with AF.
methodsIn the prospective nationwide COOL-AF registry, patients with nonvalvular AF were enrolled and followed up every 6 months until 3 years. Multimorbidity status was assessed at baseline and every 6 months. The composite outcomes were death, heart failure, major bleeding, and ischemic stroke/systemic embolism. Multimorbidity worsening was defined as an increase in multimorbidity group at 1 year.
resultsA total of 3,096 patients were studied (mean age: 67.6 ± 11.1 years; 41.8% female). Four patient groups were derived from 3,096 patients as follows: low (0-1), n = 833 (26.9%); moderate (2), n = 779 (25.2%); high (3), n = 653 (21.1%); and very high comorbidities (≥4), n = 831 (26.8%). The median duration of follow-up was 24.3 months (IQR: 23.4-24.8 months; mean: 23.0 ± 4.4 months). Patients with multimorbidity worsening had an increased risk of composite outcomes (adjusted HR: 1.39; 1.13-1.71), compared to patients with no change in multimorbidity status). Patients with ABC pathway compliance were associated with a lower risk of the composite outcome, both in patients with multimorbidity worsening (HR: 0.49; 95% CI: 0.32-0.75) and "no change" groups (HR: 0.56; 95% CI: 0.45-0.70).
conclusionsPatients with multimorbidity worsening had an increased risk of adverse outcomes, which were mitigated by ABC pathway compliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.